The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.It should be noted that the reported patient effect(s) of stenosis and angina are listed in the xience sierra everolimus eluting coronary stent systems instructions for use as a known patient effect(s) of coronary procedures.A conclusive cause for the reported patient effect(s), and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
Patient id: (b)(6).It was reported that on (b)(6) 2019, the patient presented with a mid-right coronary artery (rca), 80% stenosed lesion and a percutaneous coronary intervention (pci) was performed.Pre-dilatation was performed on the mid rca and a 2.5x23mm (1500250-23, 9080641) and 3.0x28mm (1500300-28, 9081641) xience sierra stents were implanted with acceptable results.On (b)(6) 2020, the patient had presented with angina and a positive stress test with st depression in v4-v6 leads.On (b)(6) 2021, a diagnostic coronary angiogram was performed with moderate (40%) stenosis just before the previously implanted, mid rca 3.0x28mm xience sierra stent.The mid rca 2.5x23mm xience sierra stent remained patent.Additional hospitalization was not required, and no treatment was provided.No additional information was provided regarding this issue.
|